Anti-Cancer Agent “Avastin," Obtained Approval for Additional Indication and Dosage and Administration of Malignant Glioma

The Company's Official Page
http://www.chugai-pharm.co.jp/hc/ss/english/news/detail/20130614150002.html
Back To Previous Page

Translation

Jun 14, 2013

Anti-Cancer Agent “Avastin®,"
Obtained Approval for Additional Indication and
Dosage and Administration of Malignant Glioma

June 14, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, “Chugai”)] announced today that it obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on June 14, 2013, for the additional indication and dosage and administration of “Malignant glioma,” for the anti-cancer agent / anti-VEGF humanized monoclonal antibody, "AVASTIN® I.V


Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. Press Release relating to FDA Approval f...
Hisamitsu Pharmaceutical Co., Inc. 2008/02/22
2. Hisamitsu Announces U.S. Launch of its &...
Hisamitsu Pharmaceutical Co., Inc. 2010/03/25
3. Phase II study results of HOB-294 (trans...
Hisamitsu Pharmaceutical Co., Inc. 2009/08/06
4. Notice Regarding Worldwide Patent and Kn...
Mitsubishi Tanabe Pharma Corporation 2015/09/17
5. Announcement of FY2015 2nd Quarter Finan...
Mitsubishi Tanabe Pharma Corporation 2015/10/30

Latest News: Chugai Pharmaceutical Co., Ltd.


Most Popular: Chugai Pharmaceutical Co., Ltd.

1. Chugai Presents"Volunteer for Life:...
2009/11/11

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us